

## Immunometabolism

### References and Suggested Readings

1. van Himbergen TM, Beiser AS, Ai M, et al. Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and alzheimer disease: results from the Framingham Heart Study. *Arch Neurol*. 2012;69(5):594-600.
2. Nowak C, Sundström J, Gustafsson S, et al. Protein Biomarkers for Insulin Resistance and Type 2 Diabetes Risk in Two Large Community Cohorts. *Diabetes*. 2015;65(1):276-84.
3. Achari AE, Jain SK. Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction. *Int J Mol Sci*. 2017;18(6):1321. Published 2017 Jun 21. doi:10.3390/ijms18061321
4. Spomenka Ljubic, Anamarija Jazbec, Martina Tomic, et al., "Inverse Levels of Adiponectin in Type 1 and Type 2 Diabetes Are in Accordance with the State of Albuminuria," *International Journal of Endocrinology*, vol. 2015, Article ID 372796, 8 pages, 2015. <https://doi.org/10.1155/2015/372796>.
5. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation. Geneva: World Health Organization; 2011. 2, Glycated haemoglobin (HbA1c) for the diagnosis of diabetes. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK304271/>
6. Incani M, Sentinelli F, Perra L, et al. Glycated hemoglobin for the diagnosis of diabetes and prediabetes: Diagnostic impact on obese and lean subjects, and phenotypic characterization. *J Diabetes Investig*. 2014;6(1):44-50.
7. Luft VC, Pereira M, Pankow JS, et al. Retinol binding protein 4 and incident diabetes--the Atherosclerosis Risk in Communities Study (ARIC Study). *Rev Bras Epidemiol*. 2013;16(2):388-97.
8. Strowski, MZ. Impact on FGF21 on glycemic control. *Horm Mol Biol Clin Investig*. 2017; 30(3). doi: 10.1515/hmbci-2017-0001.
9. Jimenez, V., Jambrina, C., Casana E., et al. FGF21 gene therapy as treatment for obesity and insulin resistance. *EMBO Molecular Medicine*. 2018; e8791. doi: 10.15252/emmm.201708791
10. Moschen, AR., Adolph, TE., Gerner RR., et al. Lipocalin-2: A master mediator of intestinal and metabolic inflammation. *Trends Endocrinol Metab*. 2017; 28(5): 388-397. doi: 10.1016/j.tem.2017.01.003
11. Furuhashi M, Saitoh S, Shimamoto K, Miura T. Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases. *Clin Med Insights Cardiol*. 2015;8(Suppl 3):23-33. Published 2015 Feb 2. doi:10.4137/CMC.S17067
12. Pham, CT. Neutrophil serine proteases: specific regulators of inflammation. *Nat Rev Immunol*. 2006; 6(7): 541-550.
13. Wang, Y., Xiao, Y., Zhong, L., et al. Increased neutrophil elastase and proteinase 3 and augmented NETosis are closely associated with  $\beta$ -cell autoimmunity in patients with type 1 diabetes. *Diabetes*. 2014;63(12): 4239-48.
14. Devaraj S, Singh U, Jialal I. Human C-reactive protein and the metabolic syndrome. *Curr Opin Lipidol*. 2009;20(3): 182-9.
15. Myers MG, Leibel RL, Seeley RJ, Schwartz MW. Obesity and leptin resistance: distinguishing cause from effect. *Trends Endocrinol Metab*. 2010;21(11):643-51.
16. Makris MC, Alexandrou A, Papatsoutsos EG, et al. Ghrelin and Obesity: Identifying Gaps and Dispelling Myths. A Reappraisal. *In Vivo*. 2017;31(6):1047-1050.
17. Barutcuoglu, B., Basol, G., Cakir, Y., et al. Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome. *Ann Clin Lab Sci*. 2011;41(4):390-396.
18. Zhou Y, Jiang L, Rui L. Identification of MUP1 as a regulator for glucose and lipid metabolism in mice. *J Biol Chem*. 2009;284(17):11152-9.
19. Hui X, Zhu W, Wang Y, et al. Major urinary protein-1 increases energy expenditure and improves glucose intolerance through enhancing mitochondrial function in skeletal muscle of diabetic mice. *J Biol Chem*. 2009;284(21):14050-7.
20. Kodaman N, Aldrich MC, Sobota R, et al. Plasminogen Activator Inhibitor-1 and Diagnosis of the Metabolic Syndrome in a West African Population. *J Am Heart Assoc*. 2016;5(10):e003867. Published 2016 Oct 3. doi:10.1161/JAHA.116.003867

21. Setoh K, Terao C, Muro S, et al. Three missense variants of metabolic syndrome-related genes are associated with alpha-1 antitrypsin levels. *Nat Commun.* 2015;6:7754. Published 2015 Jul 15. doi:10.1038/ncomms8754